254 related articles for article (PubMed ID: 27575807)
1. Incidence and its characteristics of repetition of reintervention after drug-eluting stent implantation for femoropopliteal lesion.
Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Yokoi H; Uematsu M;
J Vasc Surg; 2016 Dec; 64(6):1691-1695.e1. PubMed ID: 27575807
[TBL] [Abstract][Full Text] [Related]
2. The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These Lesions.
Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
JACC Cardiovasc Interv; 2016 Apr; 9(8):828-834. PubMed ID: 27101908
[TBL] [Abstract][Full Text] [Related]
3. 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
Iida O; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
JACC Cardiovasc Interv; 2015 Jul; 8(8):1105-1112. PubMed ID: 26117463
[TBL] [Abstract][Full Text] [Related]
4. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
Tran K; Ullery BW; Kret MR; Lee JT
Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
[TBL] [Abstract][Full Text] [Related]
5. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
Tsujimura T; Takahara M; Iida O; Soga Y; Katsuki T; Fujihara M; Kawasaki D; Kozuki A; Mano T
J Vasc Surg; 2021 Jun; 73(6):1998-2008.e1. PubMed ID: 33347998
[TBL] [Abstract][Full Text] [Related]
7. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
Mori S; Hirano K; Nakano M; Muramatsu T; Tsukahara R; Ito Y; Ishimori H
J Endovasc Ther; 2015 Jun; 22(3):341-9. PubMed ID: 25862363
[TBL] [Abstract][Full Text] [Related]
8. Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.
Tomoi Y; Soga Y; Iida O; Shiraki T; Kobayashi Y; Hiramori S; Ando K
J Endovasc Ther; 2016 Jun; 23(3):461-7. PubMed ID: 27004496
[TBL] [Abstract][Full Text] [Related]
9. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
[TBL] [Abstract][Full Text] [Related]
10. One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.
Bosiers M; Callaert J; Keirse K; Hendriks JMH; Peeters P; Verbist J; Maene L; Beelen R; Deloose K
J Endovasc Ther; 2017 Jun; 24(3):311-316. PubMed ID: 28351310
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Zilver PTX eluting stent in TASC C/D lesions and restenosis.
Leopardi M; Houbballah R; Becquemin JP
J Cardiovasc Surg (Torino); 2014 Apr; 55(2):229-34. PubMed ID: 24670831
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
[TBL] [Abstract][Full Text] [Related]
13. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
Bosiers M; Setacci C; De Donato G; Torsello G; Silveira PG; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Teβarek J; Giaquinta A; Wauters J
J Endovasc Ther; 2020 Apr; 27(2):287-295. PubMed ID: 31997715
[No Abstract] [Full Text] [Related]
14. Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions.
Katsuki T; Takahara M; Soga Y; Okamoto S; Iida O; Fujihara M; Kawasaki D; Ando K
J Endovasc Ther; 2019 Oct; 26(5):593-599. PubMed ID: 31431154
[TBL] [Abstract][Full Text] [Related]
15. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
J Endovasc Ther; 2016 Oct; 23(5):701-7. PubMed ID: 27193308
[TBL] [Abstract][Full Text] [Related]
16. A single center experience of Zilver PTX for femoro-popliteal lesions.
Kang WY; Campia U; Didier RJ; Kiramijyan S; Koifman E; Negi SI; Lipinski MJ; Baker NC; Escarcega RO; Torguson R; Waksman R; Bernardo NL
Cardiovasc Revasc Med; 2016 Sep; 17(6):399-403. PubMed ID: 27496591
[TBL] [Abstract][Full Text] [Related]
17. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study.
Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O
J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel exposure and long-term mortality of patients treated with the Zilver PTX drug-eluting stent.
Stern JR; Tran K; Chandra V; Harris EJ; Lee JT
Vascular; 2021 Aug; 29(4):567-573. PubMed ID: 33054678
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.
Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
J Endovasc Ther; 2014 Aug; 21(4):485-92. PubMed ID: 25101575
[TBL] [Abstract][Full Text] [Related]
20. Bare Metal Versus Paclitaxel-Eluting Stents for Long Femoropopliteal Lesions: Prospective Cohorts Comparison Using a Propensity Score-Matched Analysis.
Vent PA; Kaladji A; Davaine JM; Guyomarch B; Chaillou P; Costargent A; Quillard T; Gouëffic Y
Ann Vasc Surg; 2017 Aug; 43():166-175. PubMed ID: 28300676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]